SEC Form 4 · accession 0001140361-16-060607
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Apr 5, 2016
Accepted (ET)
Apr 7, 2016 · 8:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 5, 2016 | M | 1,500 | $14.39 | A | 393,721 | D | |
| Common Stock | Apr 6, 2016 | M | 1,500 | $14.39 | A | 395,221 | D | |
| Common Stock | holding | — | — | — | 25,758 | I | Shares held by Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Common StockF1 | $14.39 | Apr 5, 2016 | M | 1,500 | D | Nov 12, 2009 | May 11, 2019 | Common Stock | 1,500 | 238,500 | D |
| Stock Option (right to buy) Common StockF1 | $14.39 | Apr 6, 2016 | M | 1,500 | D | Nov 12, 2009 | May 11, 2019 | Common Stock | 1,500 | 237,000 | D |
Explanation of responses
- F1Reflects the numbers of stock options outstanding after the transaction from this specific stock option grant.